BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33194720)

  • 1. Genomic Profiling Comparison of Germline
    Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
    Front Oncol; 2020; 10():583314. PubMed ID: 33194720
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 3. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
    Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
    Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
    Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
    Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of BRCA1-related germline mutations in triple-negative breast tumors.
    Kotoula V; Fostira F; Papadopoulou K; Apostolou P; Tsolaki E; Lazaridis G; Manoussou K; Zagouri F; Pectasides D; Vlachos I; Tikas I; Lakis S; Konstantopoulou I; Pentheroudakis G; Gogas H; Papakostas P; Christodoulou C; Bafaloukos D; Razis E; Karavasilis V; Bamias C; Yannoukakos D; Fountzilas G
    Am J Cancer Res; 2017; 7(1):98-114. PubMed ID: 28123851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between
    Chen H; Wu J; Zhang Z; Tang Y; Li X; Liu S; Cao S; Li X
    Front Pharmacol; 2018; 9():909. PubMed ID: 30186165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of
    Pogoda K; Niwińska A; Sarnowska E; Nowakowska D; Jagiełło-Gruszfeld A; Siedlecki J; Nowecki Z
    J Oncol; 2020; 2020():8545643. PubMed ID: 32322271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
    Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of germline
    Villarreal-Garza C; Ferrigno AS; Aranda-Gutierrez A; Frankel PH; Ruel NH; Fonseca A; Narod S; Chavarri-Guerra Y; Sifuentes E; Magallanes-Hoyos MC; Herzog J; Castillo D; Alvarez-Gomez RM; Mohar-Betancourt A; Weitzel JN
    Cancer Res Commun; 2021 Dec; 1(3):140-147. PubMed ID: 35875314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
    Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University.
    Oranratnachai S; Yamkaew W; Tunteeratum A; Sukarayothin T; Iemwimangsa N; Panvichien R
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1664. PubMed ID: 35778884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
    Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
    Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.